References
- Cameron MH , WagnerJM . Gait abnormalities in multiple sclerosis: pathogenesis, evaluation, and advances in treatment . Curr. Neurol. Neurosci. Rep.11 ( 5 ), 507 – 515 ( 2011 ).
- Cohen JA , RudickRA . Aspects of multiple sclerosis that relate to trial design and clinical management . In : Multiple Sclerosis Therapeutics . CohenJA, RudickRA ( Eds ). Taylor & Francis, Boca Raton, FL, USA, 3 – 23 ( 2007 ).
- Givon U , ZeiligG, AchironA . Gait analysis in multiple sclerosis: characterization of temporal-spatial parameters using GAITRite functional ambulation system . Gait Posture29, 138 – 142 ( 2009 ).
- Martin CL , PhillipsBA, KilpatrickTJet al. Gait and balance impairment in early multiple sclerosis in the absence of clinical disability . Mult. Scler.12, 620 – 628 ( 2006 ).
- Thoumie P , LamotteD, CantalloubeS, FaucherM, AmarencoG . Motor determinants of gait in 100 ambulatory patients with multiple sclerosis . Mult. Scler.11, 485 – 491 ( 2005 ).
- Gehlsen G , BeekmanK, AssmannN, WinantD, SeidleM, CarterA . Gait characteristics in multiple sclerosis: progressive changes and effects of exercise on parameters . Arch. Phys. Med. Rehabil.67, 536 – 539 ( 1986 ).
- Crenshaw SJ , RoyerTD, RichardsJG, HudsonDJ . Gait variability in people with multiple sclerosis . Mult. Scler.12, 613 – 619 ( 2006 ).
- Remelius JG , HamillJ, Kent-BraunJ, Van EmmerikRE . Gait initiation in multiple sclerosis . Motor Control12, 93 – 108 ( 2008 ).
- Cutter GR , BaierML, RudickRAet al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure . Brain122, 871 – 882 ( 1999 ).
- Hobart JC , RiaziA, LampingDL, FitzpatrickR, ThompsonAJ . Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12) . Neurology60, 31 – 36 ( 2003 ).
- Hayes KC . The use of 4-aminopyridine (fampridine) in demyelinating disorders . CNS Drug Rev.10, 295 – 316 ( 2004 ).
- Judge SIV , BeverCTJr . Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment . Pharmacol. Ther.111, 224 – 259 ( 2006 ).
- Schwid SR , PetrieMD, McDermottMP, TierneyDS, MasonDH, GoodmanAD . Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis . Neurology48, 817 – 821 ( 1997 ).
- Goodman AD , CohenJA, CrossAet al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study . Mult. Scler.13, 357 – 368 ( 2007 ).
- Goodman AD , BrownTR, CohenJAet al. Fampridine MS-F202 Study Group. Dose comparison trial of sustained-release fampridine in multiple sclerosis . Neurology71, 1134 – 1141 ( 2008 ).
- Korenke AR , RiveyMP, AllingtonDR . Sustained-release fampridine for symptomatic treatment of multiple sclerosis . Ann. Pharmacother.42 ( 10 ), 1458 – 1465 ( 2008 ).
- Goodman AD , BrownTR, KruppLBet al. Sustained-release oral fampridine in multiple sclerosis: a randomized, double-blind, controlled trial . Lancet373, 732 – 738 ( 2009 ).
- Goodman AD , BrownTR, EdwardsKRet al. A Phase 3 trial of extended release oral dalfampridine in multiple sclerosis . Ann. Neurol.68, 494 – 502 ( 2010 ).
- Acorda Therapeutics . Acorda Therapeutics presents data from its Phase 3 study of fampridine-SR in multiple sclerosis at the American Academy of Neurology meeting . http://phx.corporateir.net/phoenix.zhtml?c=194451&p=irolnewsArticle_Print&ID=994749&highlight .
- Goodman A , SchwidS, BrownTet al. A Phase 3, multi-center trial of oral, sustained-release fampridine (4-aminopyridine) in multiple sclerosis (abstract). American Academy of Neurology . www.abstracts2view.com/aan2007boston/html/S32.003.html .
- Acorda Therapeutics . Acorda Therapeutics announces positive data from second Phase 3 study of fampridine-SR on walking ability in people with multiple sclerosis . http://phoenix.corporate-ir.net/phoenix.zhtml?c=194451&p=irol-newsArticle&ID=1083023&highlight .
- Schwid SR , GoodmanAD, MattsonDHet al. The measurement of ambulatory impairment in multiple sclerosis . Neurology49, 1419 – 1424 ( 1997 ).
- Kaufman M , MoyerD, NortonJ . The significant change for the Timed 25-foot walk in the multiple sclerosis functional composite . Mult. Scler.6, 286 – 290 ( 2000 ).
- Schwid SR , GoodmanAD, McDermottMP, BeverCF, CookSD . Quantitative functional measures in MS: what is a reliable change?Neurology58, 1294 – 1296 ( 2002 ).
- Kragt JJ , van der LindenFAH, NielsenJM, UitdehaagBMJ, PolmanCH . Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis . Mult. Scler.12, 594 – 598 ( 2006 ).